Our purpose was to determine whether the in vitro (or "spiked curve") Intravenous unfractionated heparin (UFH) therapy is used for a broad range of treatment protocols, most commonly, treatment of venous thromboembolic disease and acute coronary syndrome. 1 Therapeutic levels must be achieved rapidly and maintained within the therapeutic range to prevent recurrent thrombosis and decrease the risk of bleeding. 1,2 Unfortunately, UFH therapy must be monitored daily. The most common and cost-effective monitor is the activated partial thromboplastin time (APTT). 3 Numerous commercial APTT reagents are available, each with its own sensitivity to UFH, making the APTT difficult to standardize. 4 Two APTT-based methods for determining a therapeutic heparin range have been used to monitor UFH levels. The first uses ex vivo plasma samples to compare the APTT with the UFH concentration. 3, 5, 6 This results in a therapeutic range based on the in vivo UFH level in the patient. The second method uses diluted UFH added to a normal human plasma pool in a dose-dependent manner to determine the therapeutic heparin range (the in vitro, or "spiked curve," method). [7] [8] [9] [10] For small hospital laboratories, the ex vivo method may be difficult to impossible. Obtaining an adequate number of fresh heparinized plasma samples to determine the range may take weeks to months. In many instances, the method of adding UFH ("spiking") to normal plasma to determine the range in small hospitals is the easier or preferred method.
Intravenous unfractionated heparin (UFH) therapy is used for a broad range of treatment protocols, most commonly, treatment of venous thromboembolic disease and acute coronary syndrome. 1 Therapeutic levels must be achieved rapidly and maintained within the therapeutic range to prevent recurrent thrombosis and decrease the risk of bleeding. 1, 2 Unfortunately, UFH therapy must be monitored daily. The most common and cost-effective monitor is the activated partial thromboplastin time (APTT). 3 Numerous commercial APTT reagents are available, each with its own sensitivity to UFH, making the APTT difficult to standardize. 4 Two APTT-based methods for determining a therapeutic heparin range have been used to monitor UFH levels. The first uses ex vivo plasma samples to compare the APTT with the UFH concentration. 3, 5, 6 This results in a therapeutic range based on the in vivo UFH level in the patient. The second method uses diluted UFH added to a normal human plasma pool in a dose-dependent manner to determine the therapeutic heparin range (the in vitro, or "spiked curve," method). [7] [8] [9] [10] For small hospital laboratories, the ex vivo method may be difficult to impossible. Obtaining an adequate number of fresh heparinized plasma samples to determine the range may take weeks to months. In many instances, the method of adding UFH ("spiking") to normal plasma to determine the range in small hospitals is the easier or preferred method.
Although this in vitro method has been criticized, [8] [9] [10] evaluation for multiple reagents and lots has not been done. The purpose of this study was to evaluate multiple reagents for the accuracy of the APTT assessment of the UFH concentration based on the in vitro method. We evaluated the precision and accuracy of the in vitro method for multiple reagents to provide reliable data. Because this study was not a
Materials and Methods

Samples and Sample Processing
Samples from patients receiving intravenous UFH in a range of therapeutic doses but not receiving any other anticoagulant (oral anticoagulant or fibrinolytic therapy) were used in this study. 6, 11 The baseline APTT and prothrombin time values were normal, and there was no evidence of lupus anticoagulant, liver disease, or factor deficiency (as determined by patient record or testing). Each sample was initially obtained for the clinical monitoring of heparin. The remaining plasma used in this study was considered discarded, and no informed consent was necessary. No identifying information about patients was available to the researchers other than UFH concentration, the APTT value during heparin therapy, and that the initial prothrombin time and APTT values were within normal limits.
All samples were from venous blood specimens collected in 3.2% buffered sodium citrate anticoagulant Vacutainer tubes (BD, Franklin Lakes, NJ). 6, 11 Plasma was prepared within 45 minutes of collection by centrifugation at 2,500g for 15 minutes according to Clinical and Laboratory Standards Institute (CLSI) guidelines. 6 Centrifuged plasma samples contain fewer than 10,000 platelets per microliter. 11 Plasma samples were transferred to polystyrene tubes and capped. All APTT assays were performed within 3 hours of sample collection. The remaining plasma was frozen for heparin determination. 6, 11 
APTT Reagents and Instruments
The reagents and instruments were obtained from commercial manufacturers. All APTT assays were done on various instruments within our routine coagulation laboratory per manufacturer instructions (BCS, Siemens, Deerfield, IL; or STA-R, Diagnostica Stago, Parsippany, NJ). The following reagents were evaluated: Actin, Actin FS, and Actin FSL (Siemens); APTT-SP, SynthASil, and SynthAFax (Instrumentation Laboratory, Bedford, MA); PTT Automate (Diagnostica Stago); and Auto APTT (Trinity, now part of Diagnostica Stago). The APTT reference range (± 2 SD) for each reagent was determined by using a minimum of 20 healthy donors. The ex vivo therapeutic heparin range was determined by the method outlined in the CLSI guidelines. 6 
Heparin Anti-Factor Xa Assay
The plasma UFH concentration was determined by using a chromogenic anti-factor Xa heparin assay (Berichrom Heparin reagent kit, Siemens, on the BCS analyzer or Rotachrom Heparin reagent kit, Diagnostica Stago, on a STA-R analyzer) per manufacturer instructions. Both assays are calibrated using the manufacturer's calibrators (assigned against the World Health Organization UFH standard). In a comparison study of the 2 heparin assays, no significant difference in the heparin values were noted between assay kits (r = 0.93; slope = 0.98; P = .73).
Determination of In Vitro (Spiking) Therapeutic Heparin Range
A normal human plasma pool (990 μL) from 25 donors was "spiked" with 10 μL of serially diluted unfractionated porcine heparin (1,000 U/mL, obtained from the pharmacy). The number of dilutions tested per curve was between 5 and 6 individual points. The APTT values determined by in vitro method used the same APTT reagent lot and instrument system that were used for the determination of ex vivo APTT values. The anti-factor Xa heparin level was determined on the spiked normal plasma pool. The heparin range tested was from 0.1 to 0.8 U/mL. The heparin concentration was then plotted against the APTT value. The APTT-heparin therapeutic range was determined between 0.3 and 0.7 U/ mL of heparin. 5, 6, 8 Ex Vivo APTT-Based Therapeutic Heparin Ranges Each patient plasma sample was assayed for an APTT value and a heparin level. The APTT-based therapeutic heparin range for each reagent was determined by using 20 to 40 plasma samples (average, 31.9) from patients receiving UFH therapy. 6 The heparin concentration in the patient samples covered the complete range of therapeutic doses. By using linear regression, the APTT values were plotted against the heparin levels with a 0.3-U/mL heparin concentration for the lower end of the therapeutic heparin range, and the APTT value that corresponded to 0.7 U/mL of heparin was designated as the upper therapeutic heparin range. 6 
Correlation of APTT Reagents With In Vitro and Ex Vivo Therapeutic Ranges
Once the therapeutic heparin ranges were determined for ex vivo and in vitro methods, the APTT values were plotted relative to each ex vivo APTT range and the heparin range.
The APTT values for each therapeutic heparin range were grouped as follows: (1) below the APTT range (subtherapeutic), (2) above the APTT range (supratherapeutic), or (3) within the APTT-heparin therapeutic range (therapeutic) for the reagent. The heparin level for each sample was plotted in relation to its respective heparin concentration (subtherapeutic, <0.3 U/mL; therapeutic, 0.3-0.7 U/mL; and supratherapeutic, >0.7 U/mL).
Statistics
All statistical determinations (descriptive statistics, linear regression, and Student t test) were calculated by using Prizm 3.02 software (Graph Pad Software, San Diego, CA). Statistical significance was set at a P value of less than .05.
Results
The calculated APTT-based therapeutic heparin ranges were determined by using the ex vivo curve method and the in vitro, or spiked curve, method for 18 lots from 8 reagents. An example of 1 of the in vitro curves (with individual points) compared with the ex vivo curve (with individual points) is shown in ❚Figure 1❚. In this single lot of reagent, the in vitro curve method calculated a therapeutic heparin range of 86 to 139 seconds, whereas the ex vivo curve method range calculated the range as 72 to 113 seconds. Evaluating all 18 lots revealed that the in vitro and ex vivo curves were statistically and clinically significantly different. In all cases, the lower and upper limits were higher for the in vitro curve method than for the ex vivo curve method ❚Table 1❚. The calculated in vitro APTT lower therapeutic heparin range limit value averaged 5.7 seconds (9.9%) higher than the ex vivo method ( Table 1 ). The lower limit varied from 2 to 11 seconds (3.13%-20.8%). The APTT-based upper limit for the calculated therapeutic heparin ranges for the in vitro curve method averaged 16.3 seconds (16.8%) higher than for the ex vivo curve method. The APTT upper-limit value for the in vitro curve method varied from 12 to 23 seconds higher (12.5% and 25.3%).
The actual calculated therapeutic heparin range using the in vitro curve method was wider than the ex vivo curve method for all reagents ❚Table 2❚. The average increase in range width of the therapeutic heparin curve for the in vitro curve compared with the ex vivo curve was 10.5 seconds for the in vitro curve method. The difference variation for all reagents averaged between 5 and 16 seconds, which equated to an average 26.8% (range, 11.9%-43.6%) increase in range width compared with the ex vivo curve method.
The lot-to-lot differences between the in vitro curve method and ex vivo curve method were similar for each reagent group (not statistically different). The average linear regression coefficient (R 2 value) for the ex vivo curve method was R 2 = 0.462 (range, 0.350-0.566), and the average linear regression coefficient for the in vitro curve method was R 2 = 0.934 (range, 0.918-0.952), making the method of determination consistent for all reagents and reagents lots.
Significant differences in clinical relevance of heparin administration were observed for 574 cases when the therapeutic heparin range for the in vitro method was compared with the ex vivo range relative to the heparin level (0.3 to 0.7 U/mL) ❚Table 3❚. The in vitro distribution of APTT values compared with the heparin concentration was significantly skewed. Because the in vitro curve was shifted higher, the number of APTT values within the correlated heparin therapeutic group was shifted lower. Therefore, a significant number of cases are classified as more underheparinized than should be clinically indicated (Table 3) .
The APTT value for the 0.7 U/mL upper limit of the in vitro (spiked curve) therapeutic heparin range method was calculated to be higher, between 0.83 and 0.95 U/mL (average, 0.88 U/mL), on the ex vivo therapeutic heparin range curve, demonstrating statistically and clinically significant discordance between the ex vivo and in vitro methods ❚Table 4❚.
Discussion
The results from this study confirm that in vitro (spiked curve), dose-dependent APTT determination of a therapeutic heparin range does not accurately reflect the ex vivo heparin levels for patients receiving UFH. This finding was observed for all 8 commercial APTT reagents tested. Similar results have been found in smaller studies. [7] [8] [9] [10] 12 The in vitro method not only increased the APTT lower and upper limits of the therapeutic range, but also generated a wider therapeutic range (Tables 1 and 2 ). The differences were statistically significant (P < .0001), with increases of about 10% for the lower limit of the range to 17% for the upper limit. It is interesting that the range was widened on average by 27%, with 1 reagent generating a 43% increase in width of the therapeutic heparin range. In absolute terms, the average heparin concentration for the in vitro (spiked curve) method was between 0.23 and 0.35 U/mL higher than the ex vivo method. These data suggest that the in vitro method could significantly mislead providers about patients' actual heparin levels ( Table 4) . There are several possible explanations for these increased therapeutic heparin limits and ranges in the in vitro curves compared with the ex vivo curves. The most likely cause is that the ex vivo samples have a different population of heparin molecules than UFH taken directly from the heparin vial. 13 The human body processes the UFH as soon as the heparin enters the bloodstream, removing specific species of heparin molecules or cleaving the larger forms into smaller, differently used molecules. 13, 14 In the in vivo situation, the larger, more thrombin-responsive forms are removed first; therefore, the APTT is not as prolonged as the UFH directly from the heparin vial. 11, 13, 14 Another contributing cause is that the in vitro ranges are determined with a normal plasma pool that has normal levels of all of the factors compared with the ex vivo method that uses each patient's plasma with potential differences in coagulation factor levels and various levels of heparin-binding proteins. 15 Various levels of antithrombin and other heparin-binding molecules are present in an individual patient's plasma, causing a potentially different response to the heparin concentration. In addition, high levels of factor VIII and other coagulation proteins in ex vivo samples can shorten the response to the heparin concentration. 16 The overall cause of the in vitro-ex vivo discrepancy may be multifactorial, making it difficult to delineate and impossible to use the in vitro curve method for determining the therapeutic heparin range.
Using an in vitro (spiked curve) therapeutic heparin range will cause a significant miscalculation of the correct therapeutic heparin concentration in patients receiving UFH. Based on our studies, if an in vitro curve is used for the therapeutic heparin range, more than 70% of the UFH levels are not correctly evaluated (Table 3) . By using our hospital's weight-based protocol, a level of 0.90 U/mL would result in stopping the heparin infusion for 30 minutes and then decreasing the heparin infusion by 100 to 300 U/h, depending on the body weight of the patient, which is a decrease of 12% to 15% representing a significant clinical change in the management of the patient. At a heparin level of 0.83 to 0.95 U/mL, the patient has a clinically significant increased risk of bleeding. Calculated subtherapeutic levels by the in vitro curve method would actually be closer to or within the ex vivo method range. Decisions to increase or decrease the UFH infusion based on this method may potentially cause significant clinical complications. The ease of use of the in vitro curve, or spiked curve, method does not outweigh the increased risk for elevated levels of UFH.
Although the use of an in vitro curve method has been discouraged over the years, some hospital laboratories still use this method under the presumption that their reagent works well with the method. 4, 6, 8, 9, 17, 18 The most common reagents used today do not provide an in vitro (spiked curve) therapeutic heparin range curve that overlays with the ex vivo therapeutic heparin range curve (Tables 1 and 2 ). Therefore, an in vitro-derived UFH monitoring range is not clinically valid and should never be used. 6, 8, 9, 17 Unfortunately, this creates a dilemma for small hospital laboratories that cannot obtain a sufficient number of samples in a reasonable time frame from patients receiving UFH. How can a hospital that receives only 1 to 5 heparinized plasma samples per week (or fewer) obtain the number of samples necessary to validate and determine an ex vivo therapeutic heparin range? There are currently only 2 recommended methods for obtaining a therapeutic heparin range (ex vivo determination and cumulative summation of difference) ❚Table 5❚. 6, 17, 18 Based on best current practice, the ex vivo method seems to provide the most clinically accurate reflection of the in vivo heparin concentration at the time of sampling. The use of the cumulative summation method (a statistical method to control for temporal and lot-to-lot drift) is a valid method that can be used if the same reagent and instrument are being used each year. 6, 17, 18 However, if a change in manufacturer takes place (new type of reagent and/or instrument), the ex vivo method must be used. 6, 17, 18 Obtaining enough samples to adequately determine the therapeutic heparin range can be accomplished by obtaining fresh plasma samples from surrounding hospital laboratories and performing the APTT and heparin levels with the new reagent within an 8-hour window. These plasma samples must be provided in transfer tubes and must not be whole blood or spun whole blood with plasma on the cell mass. 6 Another possibility is a laboratory study of the differences between fresh and frozen sample APTT values that can be performed and, if no significant differences in APTT values are observed, heparinized plasma samples can be frozen and stored. The therapeutic heparin range is then determined on the frozen samples with the new reagent and/or instrument. This method has not been well validated, so caution must be taken to use the therapeutic heparin range generated by this method.
There are several methods for determining a therapeutic heparin range independent of the size of the hospital.
However, some methods are better suited for larger laboratories or laboratories with access to fresh heparinized samples ( Table  5 ). The best method to date is the ex vivo method, but owing to the variation in the APTT assay, it may have less than optimal accuracy. 6, 17 The ex vivo method is usually performed in larger hospitals and in smaller laboratories with access to fresh ex vivo heparin samples. The cumulative summary method is a good alternative but requires a large sample base. 6, 17 For smaller hospitals, the easiest route would be to use only the heparin (anti-factor Xa) assay rather than the APTT. This method will provide a direct heparin concentration, allowing for simple assay validation using frozen samples. Using frozen samples with the ex vivo method, as discussed, is a good alternative, but the laboratory must validate the method.
There are 3 methods that are completely unacceptable: (1) using an arbitrary range, (2) using a 1.5 to 2.5 times control range, and (3) using the in vitro (spiked curve) method (Table 5) . 6, 17, 18 The therapeutic heparin range must be determined for each individual hospital laboratory using one of the scientifically sound methods. 6, 17, 18 This includes laboratories performing the evaluation themselves or having the reagentinstrument manufacturer assist in the determination of the therapeutic heparin range on behalf of the laboratory. The laboratory and the vendor must follow CLSI guidelines for determining the therapeutic heparin range. 6, 17, 18 The spiked curve method should never be used for determination of the therapeutic heparin range by the laboratory or the vendor. 
